City

Guangzhou (1)

Condition

BRAF V600 Mutation (1)

MET Exon 14 Mutation (1)

NSCLC (1)

Overall Status

Not yet recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Sun Yat-sen University (1)

Collaborator

Intervention

capmatinib (1)

dabrafenib + trametinib (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

met exon 14 mutation

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting

NSCLC
+2 more

Dabrafenib + Trametinib
Capmatinib

Guangzhou, Guangdong, China

Cancer Center of Sun-Yat Sen University

Sep 19, 2023